This is a multi-center prospective, randomized, two-arm study evaluating performance of the Cordis SMART™ Nitinol Stent System compared to balloon angioplasty. Patients will be randomized on a 1:1 basis. It is anticipated that a total of 120 patients will be entered into the study. Objective of the study is: Performance of the Cordis S.M.A.R.T.™ (CONTROL™) Nitinol Stent System for the treatment of superficial femoral artery (SFA) long de novo or restenotic lesions (≥ 70% stenosis or occlusions) in comparison with balloon angioplasty as determined by Binary Restenosis (≥50% restenosis based on a peak systolic velocity ratio ≥ 2.5) at one year as demonstrated by Duplex sonography.
The study population will consist of 120 symptomatic peripheral vascular disease patients with SFA occlusions. The disease will consist of symptomatic, de novo or restenotic occlusions (5 - 22 cm) on diagnostic imaging. The occlusions must not extend beyond the proximal popliteal artery. For the purpose of this protocol, no lesion within 3 cm of the upper part of the patella may be treated. At least one calf vessel must be patent. Reference vessel diameter must be \>= 4.0 to \<= 6.0 mm. Trial participants who meet all entry criteria, will be randomized to the SMART™ Nitinol Stent or balloon angioplasty. Patients will be followed for 12 months after the procedure. Study examinations will be done at screening, procedure time, discharge, 1, 6 and 12 months after the study procedure. This study will be conducted as an investigator initiated multicenter study with 6 study centers in Switzerland. Principal investigators will be Prof. Amann, PD Dr. med T. Pfammatter (University Hospital Zürich) and Prof. I. Baumgartner, Prof. J. Triller (University Hospital Bern).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Univeristy Hospital Bern
Bern, Switzerland
University Hospital Zurich
Zurich, Switzerland
Binary restenosis by Duplex Ultrasound.
Time frame: 1 year
Technical success defined as a successful access and deployment of the device with recanalization.
Time frame: at the time of deployment
Procedural complications.
Time frame: up to the moment the catheter sheath introducer has been removed
Procedural success as defined by successful recanalization, without the occurence of a Serious Adverse Event (SAE).
Time frame: up to the catheter sheath introducer has been removed
Occurrence of Adverse events (AE) and Serious Adverse Events (SAE) in-hospital.
Time frame: 1, 6 and 12 months
Ankle Brachial Index (ABI).
Time frame: discharge, 1, 6 and 12 months
Restenosis measured by Duplex sonography.
Time frame: 1, 6 and 12 months
Target Lesion revascularisation (TLR).
Time frame: 1 year
Target Vessel revascularisation (TVR).
Time frame: 1 year
Target Limb revascularisation.
Time frame: 1 year
The number of revascularisations in both limbs.
Time frame: 1 year
Clinical categorization of chronic limb ischemia by means of the Rutherford classification.
Time frame: 1, 6 and 12 months
Pain free and absolute walking distance (treadmill testing) as compared to baseline testing.
Time frame: 1 and 12 months post index procedure
Amputation of the index limb.
Time frame: 1 year
Cardiovascular events (ACS, TIA, stroke, vascular death).
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.